LLY
USDEli Lilly and Company Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$891.410
最高
$915.220
最低
$883.640
交易量
6.58M
公司基本面
市值
806.5B
行業
Drug Manufacturers - General
國家
United States
交易統計
平均交易量
4.52M
交易所
NYQ
貨幣
USD
52週範圍
AI分析報告
最後更新: 2025年11月3日Eli Lilly (LLY): Navigating Growth Amid Competitive Obesity Drug Landscape
Market Snapshot
Current Price: $896.53 (as of 2025-11-03) 52-Week Range: $623.78 - $935.63 Volume Surge: 5.4M shares traded today vs. average of 4.5M
Key Trends Driving Recent Performance
- Obesity Drug Dominance:
- LLY announced a €2.6B Dutch plant to boost production of its weight-loss pill orfaglipron, signaling aggressive scaling.
- Partnerships like the Walmart Zepbound retail rollout (mid-Nov 2025) expand market access.
- Analyst Optimism:
- 27 analysts maintain "Buy" ratings; average price target of $919.
相關新聞
Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarter
Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a boost to the Danish drugmaker's new CEO amid a deep restructuring drive to claw back lost ground in a fierce obesity drug market battle.
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports
Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss drugs at $149 per month, in exchange for Medicare coverage, Endpoints News reported on Tuesday, citing sources familiar with the matter.
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight
Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer.
Novo Nordisk says Metsera bid won't raise antitrust issues
Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market.
Lilly to build $3 billion Dutch plant to boost weight-loss pill production
Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other oral medicines.
AI預測Beta
AI推薦
更新於: 2025年11月5日 上午06:40
54.3% 信心度
風險與交易
入場點
$862.58
獲利了結
$880.15
止損
$837.81
關鍵因素
相關股票
保持更新
設定價格提醒，獲取AI分析更新和即時市場新聞。